{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T04:03:29Z","timestamp":1793678609769,"version":"4.5.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Primary systemic vasculitis (PSV) is a heterogeneous group of autoimmune conditions. There is an unmet need for alternative therapies that lead to sustained remission in patients with refractory disease. Alemtuzumab, an anti-CD52 antibody, depletes lymphocytes for prolonged periods and, in retrospective studies, has induced sustained, treatment-free remissions in patients with refractory\/relapsing vasculitis but has raised safety concerns of infection and secondary autoimmunity. This phase IIb clinical trial aimed to assess the efficacy and safety of alemtuzumab, at two different doses, in inducing remission in refractory vasculitis patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The ALEVIATE trial was a randomised, prospective, open-label, dose ranging clinical trial. Patients with refractory ANCA-associated vasculitis (AAV) or Beh\u00e7et\u2019s disease (BD) were randomised to receive either 60\u2009mg or 30\u2009mg alemtuzumab. Treatments were administered at baseline and 6\u2009months or earlier where clinically appropriate. A maximum of three treatments were allowed within the 12-month study period.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Twenty-three patients received at least one dose of alemtuzumab. Twelve had AAV, and 11 a diagnosis of BD. The median age was 40\u2009years (range 28\u201344), with a prior disease duration of 61\u2009months (42\u2013103). Sixteen (70%) achieved either complete (6\/23, 26%) or partial (10\/23, 44%) response at 6\u2009months. Eight (35%) maintained remission to the end of the trial without relapse. Ten severe adverse events were observed in 7 (30%) patients; 4 were related to alemtuzumab. There were no differences in clinical endpoints between the 60 and 30\u2009mg alemtuzumab treatment groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>In a selected group of refractory vasculitis patients, alemtuzumab led to remission in two thirds of patients at 6 months. Remission was maintained to 12\u2009months in a third of the patients, and the safety profile was acceptable.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">ClinicalTrials.gov<\/jats:ext-link> identifier: NCT01405807, EudraCT Number: 2009-017087-17. Registered on April 07, 2011.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-022-02761-6","type":"journal-article","created":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T10:13:27Z","timestamp":1648808007000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Alemtuzumab for refractory primary systemic vasculitis\u2014a randomised controlled dose ranging clinical trial of efficacy and safety (ALEVIATE)"],"prefix":"10.1186","volume":"24","author":[{"given":"Seerapani","family":"Gopaluni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rona","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Goymer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh","family":"Cahill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Broadhurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Wallin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"McClure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afzal","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Jayne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,1]]},"reference":[{"issue":"1","key":"2761_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.37715","volume":"65","author":"JC Jennette","year":"2013","unstructured":"Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised international Chapel Hill consensus conference nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1\u201311 [cited 2014 Jul 10]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23045170.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2761_CR2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/0002-9343(67)90144-1","volume":"43","author":"PP Frohnert","year":"1967","unstructured":"Frohnert PP, Sheps SG. Long-term follow-up study of periarteritis nodosa. Am J Med. 1967;43(1):8\u201314 [cited 2015 Apr 13]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/4157287.","journal-title":"Am J Med"},{"issue":"3","key":"2761_CR3","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1136\/ard.2010.137778","volume":"70","author":"O Flossmann","year":"2011","unstructured":"Flossmann O, Berden A, de Groot K, Hagen C, Harper L, Heijl C, et al. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis. 2011;70(3):488\u201394.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"2761_CR4","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/S0272-6386(03)00025-8","volume":"41","author":"AD Booth","year":"2003","unstructured":"Booth AD, Almond MK, Burns A, Ellis P, Gaskin G, Neild GH, et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis. 2003;41(4):776\u201384.","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"2761_CR5","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1002\/art.21142","volume":"52","author":"K De Groot","year":"2005","unstructured":"De Groot K, Rasmussen N, Bacon PA, JWC T, Feighery C, Gregorini G, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005;52(8):2461\u20139 [cited 2014 Dec 1]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16052573.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"2761_CR6","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa020286","volume":"349","author":"D Jayne","year":"2003","unstructured":"Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JWC, Dadonien\u00e9 J, et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003;349(1):36\u201344 [cited 2015 Mar 21]. Available from: http:\/\/www.nejm.org\/doi\/abs\/10.1056\/NEJMoa020286.","journal-title":"N Engl J Med"},{"key":"2761_CR7","doi-asserted-by":"publisher","unstructured":"Robson J, Doll H, Suppiah R, Flossmann O, Harper L, H\u00f6glund P, et al. Damage in the ANCA-associated vasculitides: long-term data from the European Vasculitis study group (EUVAS) therapeutic trials. Ann Rheum Dis. 2015;74(1):177\u201384. [cited 2017 Feb 28]. Available from: https:\/\/doi.org\/10.1136\/annrheumdis-2013-203927.","DOI":"10.1136\/annrheumdis-2013-203927"},{"issue":"1","key":"2761_CR8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.semarthrit.2010.09.002","volume":"41","author":"A Arida","year":"2011","unstructured":"Arida A, Fragiadaki K, Giavri E, Sfikakis PP. Anti-TNF agents for Beh\u00e7et\u2019s disease: analysis of published data on 369 patients. Semin Arthritis Rheum. 2011;41(1):61\u201370 [cited 2021 Nov 2]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21168186.","journal-title":"Semin Arthritis Rheum"},{"issue":"3 Suppl 72","key":"2761_CR9","first-page":"S62","volume":"30","author":"S Furuta","year":"2012","unstructured":"Furuta S, Chow YW, Chaudhry AN, Jayne D. Switching of anti-TNF-\u03b1 agents in Beh\u00e7et\u2019s disease. Clin Exp Rheumatol. 2012;30(3 Suppl 72):S62\u20138 [cited 2015 Aug 27]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23010387.","journal-title":"Clin Exp Rheumatol"},{"key":"2761_CR10","doi-asserted-by":"publisher","first-page":"504","DOI":"10.3389\/fimmu.2014.00504","volume":"5","author":"LL Lintermans","year":"2014","unstructured":"Lintermans LL, Stegeman CA, Heeringa P, Abdulahad WH. T cells in vascular inflammatory diseases. Front Immunol. 2014;5:504 [cited 2021 Nov 2]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25352848.","journal-title":"Front Immunol"},{"issue":"4","key":"2761_CR11","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.autrev.2017.12.002","volume":"17","author":"A von Borstel","year":"2018","unstructured":"von Borstel A, Sanders JS, Rutgers A, Stegeman CA, Heeringa P, Abdulahad WH. Cellular immune regulation in the pathogenesis of ANCA-associated vasculitides. Autoimmun Rev. 2018;17(4):413\u201321. https:\/\/doi.org\/10.1016\/j.autrev.2017.12.002.","journal-title":"Autoimmun Rev"},{"issue":"12","key":"2761_CR12","doi-asserted-by":"publisher","first-page":"5867","DOI":"10.4049\/jimmunol.1301926","volume":"191","author":"X Zhang","year":"2013","unstructured":"Zhang X, Tao Y, Chopra M, Ahn M, Marcus KL, Choudhary N, et al. Differential reconstitution of T cell subsets following immunodepleting treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with relapsing\u2013remitting multiple sclerosis. J Immunol. 2013;191(12):5867\u201374 [cited 2021 Nov 2]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24198283.","journal-title":"J Immunol"},{"issue":"9","key":"2761_CR13","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1136\/ard.2007.081661","volume":"67","author":"M Walsh","year":"2008","unstructured":"Walsh M, Chaudhry A, Jayne D. Long-term follow-up of relapsing\/refractory anti-neutrophil cytoplasm antibody associated vasculitis treated with the lymphocyte depleting antibody alemtuzumab (CAMPATH-1H). Ann Rheum Dis. 2008;67(9):1322\u20137 [cited 2014 Nov 6]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18055469.","journal-title":"Ann Rheum Dis"},{"key":"2761_CR14","doi-asserted-by":"crossref","unstructured":"Mohammad AJ, Smith RM, Chow YW, Chaudhry AN, Jayne DRW. Alemtuzumab as remission induction therapy in Behcet disease: a 20-year experience. J Rheumatol. 2015; Available from: http:\/\/www.jrheum.org\/cgi\/doi\/10.3899\/jrheum.141344.","DOI":"10.3899\/jrheum.141344"},{"issue":"12","key":"2761_CR15","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1093\/rheumatology\/keg424","volume":"42","author":"CM Lockwood","year":"2003","unstructured":"Lockwood CM, Hale G, Waldman H, Jayne DRW. Remission induction in Beh\u00e7et\u2019s disease following lymphocyte depletion by the anti-CD52 antibody CAMPATH 1-H. Rheumatology (Oxford). 2003;42(12):1539\u201344 [cited 2014 Dec 1]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12949252.","journal-title":"Rheumatology (Oxford)"},{"issue":"9856","key":"2761_CR16","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","volume":"380","author":"JA Cohen","year":"2012","unstructured":"Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1819\u201328 [cited 2021 Nov 2]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23122652.","journal-title":"Lancet"},{"issue":"9856","key":"2761_CR17","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","volume":"380","author":"AJ Coles","year":"2012","unstructured":"Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1829\u201339 [cited 2021 Nov 3]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23122650.","journal-title":"Lancet"},{"key":"2761_CR18","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1093\/rheumatology\/38.8.728","volume":"38","author":"BB Bhakta","year":"1999","unstructured":"Bhakta BB, Brennan P, James TE, Chamberlain MA, Noble BA, Silman AJ. Beh\u00e7et\u2019s disease: evaluation of a new instrument to measure clinical activity. Rheumatology (Oxford). 1999;38:728\u201333.","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"2761_CR19","doi-asserted-by":"publisher","first-page":"3760","DOI":"10.1002\/art.34583","volume":"64","author":"RM Smith","year":"2012","unstructured":"Smith RM, Jones RB, Guerry M-J, Laurino S, Catapano F, Chaudhry A, et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2012;64(11):3760\u20139 [cited 2014 Nov 12]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22729997.","journal-title":"Arthritis Rheum"},{"issue":"7","key":"2761_CR20","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1136\/ard.2008.092429","volume":"68","author":"O Flossmann","year":"2009","unstructured":"Flossmann O, Baslund B, Bruchfeld A, Cohen Tervaert JW, Hall C, Heinzel P, et al. Deoxyspergualin in relapsing and refractory Wegener\u2019s granulomatosis. Ann Rheum Dis. 2009;68(7):1125\u201330 [cited 2021 Nov 3]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18713783.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2761_CR21","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1093\/rheumatology\/39.6.585","volume":"39","author":"D Jayne","year":"2000","unstructured":"Jayne D. Evidence-based treatment of systemic vasculitis. Rheumatology (Oxford). 2000;39(6):585\u201395 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/10888702.","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"2761_CR22","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1136\/ard.2009.109389","volume":"69","author":"MA Little","year":"2010","unstructured":"Little MA, Nightingale P, Verburgh CA, Hauser T, De Groot K, Savage C, et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis. 2010;69(6):1036\u201343 [cited 2017 Feb 28]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19574233.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2761_CR23","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10875-009-9327-3","volume":"30","author":"SAJ Thompson","year":"2010","unstructured":"Thompson SAJ, Jones JL, Cox AL, Compston DAS, Coles AJ. B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis. J Clin Immunol. 2010;30(1):99\u2013105 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19763798.","journal-title":"J Clin Immunol"},{"issue":"3","key":"2761_CR24","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa0909169","volume":"363","author":"RB Jones","year":"2010","unstructured":"Jones RB, Tervaert JW, Cohen Hauser T, Luqmani R, Morgan MD, Au Peh C, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med. 2010;363(3):211\u201320.","journal-title":"N Engl J Med"},{"key":"2761_CR25","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. Rituximab versus cyclophosphamide in ANCA-associated vasculitis. N Engl J Med. 2010;363:221\u201332 [cited 2015 Mar 20]. Available from: http:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa0909905#t=article.","journal-title":"N Engl J Med"},{"issue":"19","key":"2761_CR26","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1056\/NEJMoa1404231","volume":"371","author":"L Guillevin","year":"2014","unstructured":"Guillevin L, Pagnoux C, Karras A, Khouatra C, Auma\u00eetre O, Cohen P, et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med. 2014;371(19):1771\u201380 [cited 2014 Nov 6]. Available from: http:\/\/www.nejm.org\/doi\/abs\/10.1056\/NEJMoa1404231.","journal-title":"N Engl J Med"},{"issue":"11","key":"2761_CR27","doi-asserted-by":"publisher","first-page":"3332","DOI":"10.1002\/eji.200535075","volume":"35","author":"AL Cox","year":"2005","unstructured":"Cox AL, Thompson SAJ, Jones JL, Robertson VH, Hale G, Waldmann H, et al. Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis. Eur J Immunol. 2005;35(11):3332\u201342 [cited 2021 Nov 3]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/16231285.","journal-title":"Eur J Immunol"},{"issue":"1","key":"2761_CR28","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/imm.12178","volume":"141","author":"E Havari","year":"2014","unstructured":"Havari E, Turner MJ, Campos-Rivera J, Shankara S, Nguyen T-H, Roberts B, et al. Impact of alemtuzumab treatment on the survival and function of human regulatory T cells in vitro. Immunology. 2014;141(1):123\u201331 [cited 2014 Nov 7]. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24116901.","journal-title":"Immunology."}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02761-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-022-02761-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-022-02761-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T14:07:43Z","timestamp":1648822063000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-022-02761-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,1]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["2761"],"URL":"https:\/\/doi.org\/10.1186\/s13075-022-02761-6","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,1]]},"assertion":[{"value":"22 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the NRES Committee East of England \u2013 Cambridge East. REC reference number: 10\/H0304\/64. All patients gave informed and written consent to participate in the trial have read and understood the patient information sheet.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DJ has received research grants from Chemocentryx, GSK, Roche\/Genentech and Sanofi-Genzyme and consultancy fees from Astra-Zeneca, Boehringer-Ingelheim, Chemocentryx, Chugai, GSK, Infla-RX, Insmed and Takeda. RS has received lecture fess from Roche and consultancy fees from GSK and Nordic Pharma. SG, DG, HC, EB, EW, MM, AC none.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"81"}}